Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Yuichiro� Doki
ResearcherPublications, citations & collaboration network
Yuichiro� Doki is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 2,275 works, 52,620 citations, an h-index of 103 and an i10-index of 942.
2,275
Works
52,620
Citations
103
h-index
942
i10-index
How has Yuichiro� Doki's publication output changed over time?
ScholarIQpublication output · 2010–2022
Output grew0% over the shown period — from 1 works in 2010 to 1 in 2022.
1
2
1
1
3
2
1
1
20102011201420152016201820192022
What are the most-cited papers on Yuichiro� Doki?
ScholarIQmost cited works
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Morihito Okada, Chen-Yuan Lin, Keisho Chìn, Shigenori Kadowaki, Myung‐Ju Ahn, Yasuo Hamamoto, Yuichiro� Doki, Chueh‐Chuan Yen, Yutaro Kubota, Sung‐Bae Kim, Chih‐Hung Hsu, Eva Holtved, Ioannis Xynos, Mamoru Kodani, Yuko Kitagawa
The Lancet Oncology. 20191,250 CitationsOPEN ACCESS
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Takuro Saito, Hiroyoshi Nishikawa, Hisashi Wada, Yuji Nagano, Daisuke Sugiyama, Koji Atarashi, Yuka Maeda, Masahide Hamaguchi, Naganari Ohkura, Eiichi Sato, Hirotsugu Nagase, Junichi Nishimura, Hirofumi Yamamoto, Shuji Takiguchi, Takeshi Tanoue, Wataru Suda, Hidetoshi Morita, Masahira Hattori, Kenya Honda, Masaki Mori, Yuichiro� Doki, Shimon Sakaguchi
Nature Medicine. 2016897 Citations
Reprogramming of Mouse and Human Cells to Pluripotency Using Mature MicroRNAs
Norikatsu Miyoshi, Hideshi Ishii, Hiroaki Nagano, Naotsugu Haraguchi, Dyah Laksmi Dewi, Yoshihiro Kano, Shinpei Nishikawa, Masahiro Tanemura, Koshi Mimori, Fumiaki Tanaka, Toshiyuki Saito, Junichi Nishimura, Ichiro Takemasa, Tsunekazu Mizushima, Masataka Ikeda, Hirofumi Yamamoto, Mitsugu Sekimoto, Yuichiro� Doki, Masaki Mori
S128124174. 2011755 CitationsOPEN ACCESS
CD13 is a therapeutic target in human liver cancer stem cells
Naotsugu Haraguchi, Hideshi Ishii, Koshi Mimori, Fumiaki Tanaka, Masahisa Ohkuma, Ho Min Kim, Hirofumi Akita, Daisuke Takiuchi, Hisanori Hatano, Hiroaki Nagano, Graham F. Barnard, Yuichiro� Doki, Masaki Mori
S114430552. 2010606 CitationsOPEN ACCESS
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2
Yuko Kitagawa, Takashi Uno, Tsuneo Oyama, Ken Kato, Hiroyuki Kato, Hirofumi Kawakubo, Osamu Kawamura, Motoyasu Kusano, Hiroyuki Kuwano, Hiroya Takeuchi, Yasushi Toh, Yuichiro� Doki, Yoshio Naomoto, Kenji Nemoto, Eisuke Booka, Hisahiro Matsubara, Tatsuya Miyazaki, Manabu Muto, Akio Yanagisawa, Masahiro Yoshida
S112874639. 2018593 CitationsOPEN ACCESS
Related on ScholarIQ
Osaka Gakuin University
Institution
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Paper
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Paper
Reprogramming of Mouse and Human Cells to Pluripotency Using Mature MicroRNAs
Paper
CD13 is a therapeutic target in human liver cancer stem cells
Paper
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2
Paper